In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

ContraFect Corp.. Trade Record

NASDAQ:CFRX ContraFect Corp. stock gains 18.20% Exit Feb 9, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CFRX Jan 26, 2018, priceSeries
About ContraFect Corp.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Trade Information
Trade Type
LONG
ReliabilityScore™
87.18
Entry Date
Jan 26, 2018
Entry Price
1.25
Sell Date
Feb 9, 2018
Sell Price
1.48
Net Gain
18.20%
Hold Time
10 Trading Days